Study Describes Design, Validation of Foundation Medicine's Blood-Based TMB Test

Aug 06, 2018

|

NEW YORK (GenomeWeb) – Researchers from Genentech, Foundation Medicine, UC Davis, and other medical centers, have published a report on the development and early validation of Foundation's planned blood-based tumor mutational burden test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Study Describes Design, Validation of Foundation Medicine's Blood-Based TMB Test

To read the full story....

Breaking News

Somalogic Closes $121M Series A Funding

FDA Issues EUAs for Gravity Diagnostics Coronavirus Test, Sample Self-Collection Kit from RapidRona

Kantaro Biosciences Gets FDA Emergency Use Authorization for Coronavirus Antibody Test

In Brief This Week: Quest Diagnostics, Fluidigm, BD, and More

Tempus Gets CE Mark for xT Tumor Sequencing Assay

BTIG Downgrades Fulgent Genetics from Buy to Neutral

Featured White Papers

Case Study: Deployment of High-Throughput SARS-CoV-2 Testing at UC Davis

What's Popular?

European Consortium Seeks to Develop Liquid Biopsy Test for Prostate, Testicular Cancer

FDA Accepts Invitae Premarket Approval Submission for Stratafide Companion Diagnostic

Abviris Developing Blood-Based Serology Test For HPV-Related Cancers

Tempus Gets CE Mark for xT Tumor Sequencing Assay

Three Investment Banks Initiate Coverage of Biodesix

Sponsorships